CAJ | 학술논문

背景与目的:分子靶向药物吉非替尼单药治疗晚期非小细胞肺癌具有较好的疗效和安全性.本文观察吉非替尼一线治疗晚期非小细胞肺痛的疗效和不良反应.方法:34例病理确诊的不愿或不能接受传统细胞毒性药物化疗的非小细胞肺癌患者,口服吉非替尼250 mg,每日1次,持续用药直至肿瘤进展或出现不可耐受的不良反应.结果:吉非替尼的有效率为29.4%,疾病控制率为61.8%,症状改善率为47.1%,中位无进展生存期为3.0个月,中位生存期为10.2个月,1年生存率为35.3%.其中不吸烟患者客观缓解率高于吸烟患者(P=0.023).出现皮疹患者疾病控制率高于无皮疹患者(P=0.005),Logistic回归提示皮疹是疾病控制的独立因素(P=0.003).最常见的不良反应是皮疹和腹泻.结论:对于不愿或不能接受传统细胞毒性药物化疗的非小细胞肺癌患者,吉非替尼为这些患者提供了另一个选择.
배경여목적:분자파향약물길비체니단약치료만기비소세포폐암구유교호적료효화안전성.본문관찰길비체니일선치료만기비소세포폐통적료효화불량반응.방법:34례병리학진적불원혹불능접수전통세포독성약물화료적비소세포폐암환자,구복길비체니250 mg,매일1차,지속용약직지종류진전혹출현불가내수적불량반응.결과:길비체니적유효솔위29.4%,질병공제솔위61.8%,증상개선솔위47.1%,중위무진전생존기위3.0개월,중위생존기위10.2개월,1년생존솔위35.3%.기중불흡연환자객관완해솔고우흡연환자(P=0.023).출현피진환자질병공제솔고우무피진환자(P=0.005),Logistic회귀제시피진시질병공제적독립인소(P=0.003).최상견적불량반응시피진화복사.결론:대우불원혹불능접수전통세포독성약물화료적비소세포폐암환자,길비체니위저사환자제공료령일개선택.
Background and purpose: It has been proven that gefitinib can be safely and efficiently used to treat advanced non-small cell lung cancer (NSCLC) as a molecule targeted drug. This research was aimed to investigate the efficacy and toxicity of gefitinib as the first-line therapy for advanced NSCLC. Methods: A total of 34 pathologically-confirmed NSCLC patients who were not willing to receive or tolerate traditional cytotoxic drug chemotherapy were enrolled into the study. Gefitinib was orally administered 250 mg daily until disease progression or the occurrence of intolerable toxicity. Results: The objective response rate of gefitinib was 29.4%. The disease control rate was 61.8%. The rate of symptom relief was 47.1%. The median progression-free survival was 3.0 months. The median overall survival was 10.2 months. One-year survival rate was 35.3%. The objective response rate of nun-smoker was higher than smoker (P=0.023). The disease control rate for the patients with rash toxicity after administration of the drug were higher than those without rash (P=0.005). Logistic regression showed that rash was an independent disease control factor (P=0.003). The most common drug-related adverse events were rash and diarrhea. Conclusion: Gefitinib provided another choice to patients who are unwilling or unable to be treated by chemotherapy.